Top View
- Janus Kinase Inhibitors and Fields of Usage
- Drugs of the Future: Pacritinib
- Stembook 2018.Pdf
- Protein Kinase Inhibitors for Acute Leukemia Yuan Ling, Qing Xie, Zikang Zhang and Hua Zhang*
- 2018 Medicines in Development for Cancer
- DDW Highlights June 20Th, 2018 Alain Schoepfer
- Ulipristal Acetate
- FLT3 Inhibition: a Moving and Evolving Target in Acute Myeloid Leukaemia
- Small Molecules in Targeted Cancer Therapy: Advances, Challenges, and Future Perspectives
- Phase 1/2 Study of Pacritinib, a Next Generation JAK2/FLT3 Inhibitor, in Myelofibrosis Or Other Myeloid Malignancies Srdan Verstovsek1*, Olatoyosi Odenike2, Jack W
- AHRQ Healthcare Horizon Scanning System – Status Update
- Translating Jaks to Jakinibs Massimo Gadina, Danielle A
- 2018 Annual Report
- No REC Ref Title Target No of Patients Date of End of Recruitment
- The Multi-Kinase Inhibitor Debio 0617B Reduces Maintenance and Self-Renewal of Primary Human AML CD34 Stem/Progenitor Cells
- Orphan Drug Designation List
- Cardiotoxicity of Novel Targeted Hematological Therapies
- Target Therapy in Hematological Malignancies Safa Shukry, Fadhel Hariri and Abdul Wahab Al-Nehmi
- United States Patent $835 a 88: As: Inhibitor 1-((R)-3-(4-Amino-3-(4
- COVID-19 Issues Issue 3
- Publication Final Minutes CHMP 28-31 January 2019
- WO 2016/126552 Al 11 August 2016 (11.08.2016) P O P C T
- 2020 Medicines in Development ꟷ Cancer
- CTI Biopharma 2018 Annual Report
- The Ups and Downs of STAT Inhibition in Acute Myeloid Leukemia
- Rxoutlook® 3Rd Quarter 2021
- Diapositiva 1
- 1518 JAK2 46216796 C28H32N4O3 472.58 1/7 4.499 Myelodysplastic Syndromes, Myelofibrosis
- Persistence of Myelofibrosis Treated with Ruxolitinib
- Review Article Gene Mutations and Molecularly Targeted Therapies in Acute Myeloid Leukemia
- Comprehensive Kinase Profile of Pacritinib, a Nonmyelosuppressive Janus Kinase 2 Inhibitor
- October 2017 a View Into Upcoming Specialty and Traditional Drugs TABLE of CONTENTS
- Oncology Drugs in the Pipeline
- Investor Presentation
- Stem Cell/Wnt
- Results of PAC203: a Randomized Phase 2 Dose-Finding Study and Determination of the Recommended Dose of Pacritinib in Patients with Myelofibrosis
- JAK-STAT Inhibitors in Atopic Dermatitis from Pathogenesis to Clinical Trials Results
- Specialty Pipeline Monthly Update June 2021
- Drugs Targeting the JAK/STAT Pathway for the Treatment of Immune-Mediated Inflammatory Skin Diseases: Protocol for a Scoping Review
- Characterization of the Pharmacokinetic And
- Challenges for Drug Repurposing in the COVID-19 Pandemic Era
- The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
- Medical Product Quality Report
- Rxoutlook® 1St Quarter 2021
- Pacritinib (SB1518), a JAK2/FLT3 Inhibitor for the Treatment of Acute Myeloid Leukemia
- Enpaxiq International Non-Proprietary Name: Pacritinib Procedure No. EMEA/H/C/004193/0000
- Download Clinical Trials
- Patients with FLT3-Mutant AML Needed to Enroll on FLT3-Targeted Therapeutic Clinical Trials
- Mediators of Inflammation in Myeloproliferative Neoplasms: State of the Art
- Changing the Treatment Story in Myelofibrosis New Science and More Choices for Challenging Cases in the JAK Inhibitor Era
- Selective Targeting of JAK/STAT Signaling Is Potentiated by Bcl-Xl Blockade in IL-2–Dependent Adult T-Cell Leukemia
- Efficacy and Tolerability of Janus Kinase Inhibitors In
- Comparison of Momelotinib, Pacitinib and Ruxolitinib